UCB-H

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 565634

CAS#: N/A

Description: UCB-H is a potent ligand of the synaptic vesicle protein 2a (sv2a) protein


Chemical Structure

img
UCB-H
CAS# N/A

Theoretical Analysis

MedKoo Cat#: 565634
Name: UCB-H
CAS#: N/A
Chemical Formula: C16H12F4N2O
Exact Mass: 324.0886
Molecular Weight: 324.2786
Elemental Analysis: C, 59.26; H, 3.73; F, 23.43; N, 8.64; O, 4.93

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: UCB-H; UCB H; UCBH

IUPAC/Chemical Name: 1-((3-Fluoropyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one

InChi Key: KNDCJGAPPBQUTQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H12F4N2O/c17-12-3-10(4-13(18)16(12)20)11-5-15(23)22(8-11)7-9-1-2-21-6-14(9)19/h1-4,6,11H,5,7-8H2

SMILES Code: O=C1N(CC2=C(F)C=NC=C2)CC(C3=CC(F)=C(F)C(F)=C3)C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 324.2786 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Serrano ME, Becker G, Bahri MA, Seret A, Mestdagh N, Mercier J, Mievis F, Giacomelli F, Lemaire C, Salmon E, Luxen A, Plenevaux A. Evaluating the In Vivo Specificity of [(18)F]UCB-H for the SV2A Protein, Compared with SV2B and SV2C in Rats Using microPET. Molecules. 2019 May 1;24(9). pii: E1705. doi: 10.3390/molecules24091705. PubMed PMID: 31052478; PubMed Central PMCID: PMC6538996.

2: Serrano ME, Bahri MA, Becker G, Seret A, Mievis F, Giacomelli F, Lemaire C, Salmon E, Luxen A, Plenevaux A. Quantification of [(18)F]UCB-H Binding in the Rat Brain: From Kinetic Modelling to Standardised Uptake Value. Mol Imaging Biol. 2018 Nov 20. doi: 10.1007/s11307-018-1301-0. [Epub ahead of print] PubMed PMID: 30460626.

3: Constantinescu CC, Tresse C, Zheng M, Gouasmat A, Carroll VM, Mistico L, Alagille D, Sandiego CM, Papin C, Marek K, Seibyl JP, Tamagnan GD, Barret O. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers. Mol Imaging Biol. 2019 Jun;21(3):509-518. doi: 10.1007/s11307-018-1260-5. PubMed PMID: 30084043.

4: Mercier J, Provins L, Valade A. Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications. Drug Discov Today Technol. 2017 Nov;25:45-52. doi: 10.1016/j.ddtec.2017.11.003. Epub 2017 Dec 1. Review. PubMed PMID: 29233267.

5: Bahri MA, Plenevaux A, Aerts J, Bastin C, Becker G, Mercier J, Valade A, Buchanan T, Mestdagh N, Ledoux D, Seret A, Luxen A, Salmon E. Measuring brain synaptic vesicle protein 2A with positron emission tomography and [(18)F]UCB-H. Alzheimers Dement (N Y). 2017 Aug 30;3(4):481-486. doi: 10.1016/j.trci.2017.08.004. eCollection 2017 Nov. PubMed PMID: 29124105; PubMed Central PMCID: PMC5671624.

6: Becker G, Warnier C, Serrano ME, Bahri MA, Mercier J, Lemaire C, Salmon E, Luxen A, Plenevaux A. Pharmacokinetic Characterization of [(18)F]UCB-H PET Radiopharmaceutical in the Rat Brain. Mol Pharm. 2017 Aug 7;14(8):2719-2725. doi: 10.1021/acs.molpharmaceut.7b00235. Epub 2017 Jul 13. PubMed PMID: 28651055.

7: Warnier C, Lemaire C, Becker G, Zaragoza G, Giacomelli F, Aerts J, Otabashi M, Bahri MA, Mercier J, Plenevaux A, Luxen A. Enabling Efficient Positron Emission Tomography (PET) Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) with a Robust and One-Step Radiosynthesis of a Highly Potent (18)F-Labeled Ligand ([(18)F]UCB-H). J Med Chem. 2016 Oct 13;59(19):8955-8966. Epub 2016 Sep 20. PubMed PMID: 27598384.

8: Bretin F, Bahri MA, Bernard C, Warnock G, Aerts J, Mestdagh N, Buchanan T, Otoul C, Koestler F, Mievis F, Giacomelli F, Degueldre C, Hustinx R, Luxen A, Seret A, Plenevaux A, Salmon E. Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [(18)F]UCB-H: First-in-Human Study. Mol Imaging Biol. 2015 Aug;17(4):557-64. doi: 10.1007/s11307-014-0820-6. PubMed PMID: 25595813.

9: Warnock GI, Aerts J, Bahri MA, Bretin F, Lemaire C, Giacomelli F, Mievis F, Mestdagh N, Buchanan T, Valade A, Mercier J, Wood M, Gillard M, Seret A, Luxen A, Salmon E, Plenevaux A. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. J Nucl Med. 2014 Aug;55(8):1336-41. doi: 10.2967/jnumed.113.136143. Epub 2014 Jun 16. PubMed PMID: 24935992.

10: Mercier J, Archen L, Bollu V, Carré S, Evrard Y, Jnoff E, Kenda B, Lallemand B, Michel P, Montel F, Moureau F, Price N, Quesnel Y, Sauvage X, Valade A, Provins L. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem. 2014 Apr;9(4):693-8. doi: 10.1002/cmdc.201300482. Epub 2014 Jan 20. PubMed PMID: 24446373.

11: Bretin F, Warnock G, Bahri MA, Aerts J, Mestdagh N, Buchanan T, Valade A, Mievis F, Giacomelli F, Lemaire C, Luxen A, Salmon E, Seret A, Plenevaux A. Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI Res. 2013 May 7;3(1):35. doi: 10.1186/2191-219X-3-35. PubMed PMID: 23647774; PubMed Central PMCID: PMC3655042.